Literature DB >> 9707018

Peripheral blood CD34+ cell count reliably predicts autograft yield.

P Chapple1, H M Prince, M Quinn, I Bertoncello, S Juneja, M Wolf, H Januszewicz, M Brettell, J Gardyn, C Seymour, D Venter.   

Abstract

A reliable measure to predict peripheral blood progenitor cell (PBPC) autograft CD34+ cell content is required to optimize the timing of PBPC collection. We prospectively examined the peripheral blood (PB) CD34+ cell count in 59 consecutive patients with various malignancies and analyzed the correlation between the PB CD34+ cell count and various parameters in the PBPC autograft. Two hundred and thirty-five collections were performed with a median of 4.0 collections per patient (range, 2-10). The median PB CD34+ cell count at the time of collection was 39 x 10(6)/1 (range, 0.0-285.6). The PBPC autograft parameters measured were the CD34+ cell, colony-forming unit granulocyte-macrophage (CFU-GM) and mononuclear cell (MNC) content. There was a strong linear correlation between PB CD34+ cells/l and autograft CD34+ cells/kg (r = 0.8477). The correlation with CFU-GM/kg (r = 0.5512) was weaker. There was no correlation between autograft CD34+ cells/kg and PB WBC (r= 0.0684), PB MNC (r = 0.1518) or PB platelet count (r = 0.2010). At our institution we aim to obtain a minimum of 0.5 x 10(6) CD34+ cells/kg with each day of collection. We demonstrate that such a collection can be reliably obtained if the PB CD34+ cell count exceeds 5.0 x 10(6)/l.

Entities:  

Mesh:

Year:  1998        PMID: 9707018     DOI: 10.1038/sj.bmt.1701308

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  The new Sysmex XN-2000 automated blood cell analyzer more accurately measures the absolute number and the proportion of hematopoietic stem and progenitor cells than XE-2100 when compared to flow cytometric enumeration of CD34+ cells.

Authors:  Sang Hyuk Park; Chan-Jeoung Park; Mi-Jeong Kim; Min-Young Han; Sang-Hee Han; Young-Uk Cho; Seongsoo Jang
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.